Bioline RX Ltd (NASDAQ:BLRX) – Investment analysts at Oppenheimer issued their FY2022 earnings estimates for shares of Bioline RX in a report issued on Wednesday. Oppenheimer analyst M. Breidenbach expects that the biotechnology company will post earnings per share of $0.04 for the year. Oppenheimer has a “Buy” rating and a $3.00 price objective on the stock.
Bioline RX (NASDAQ:BLRX) last posted its quarterly earnings data on Tuesday, November 21st. The biotechnology company reported ($0.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.02).
Bioline RX (NASDAQ:BLRX) traded down $0.02 during trading on Thursday, hitting $1.09. The company had a trading volume of 472,664 shares, compared to its average volume of 842,798. The firm has a market capitalization of $117.96, a price-to-earnings ratio of -3.36 and a beta of 0.88. Bioline RX has a one year low of $0.80 and a one year high of $1.38.
ILLEGAL ACTIVITY NOTICE: “Bioline RX Ltd to Post FY2022 Earnings of $0.04 Per Share, Oppenheimer Forecasts (BLRX)” was first published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/01/20/bioline-rx-ltd-to-post-fy2022-earnings-of-0-04-per-share-oppenheimer-forecasts-blrx.html.
About Bioline RX
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for Bioline RX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioline RX and related companies with MarketBeat.com's FREE daily email newsletter.